文献速递脊柱关节炎

中轴型脊柱关节炎个体化NSAID治疗:贝叶斯分析的单病例试验

Individualizing NSAID therapy in axial spondyloarthritis: N-of-1 trials with Bayesian analysis.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

本研究对42例符合ASAS标准的中轴型脊柱关节炎患者开展单病例随机双盲交叉试验,比较塞来昔布、美洛昔康和萘普生三种NSAID,每种用药4周、共两轮循环。30例完成试验,三种NSAID总体均使ASDAS下降(获益后验概率>0.99),但无单一NSAID对所有患者均优;贝叶斯分析可为每例患者识别偏好药物,偏好药物较最无效药物ASDAS降幅更大(0.88 vs 0.12,获益后验概率>0.99)。

要点

  • 三种NSAID总体均使ASDAS下降,获益后验概率>0.99,但无单一药物对所有患者均优。
  • 贝叶斯分析可为每例患者识别偏好NSAID,偏好药物较最无效药物ASDAS降幅更大(0.88 vs 0.12)。
  • 作者认为单病例试验联合贝叶斯分析可优化中轴型脊柱关节炎的NSAID治疗。

核心结论

  • 应用单病例试验和贝叶斯分析可从中轴型脊柱关节炎的疗效及副作用方面优化NSAID治疗。
  • 作者认为该方式可能比常规诊疗更高效地实现系统性个体化。

研究设计与样本

  • 单病例试验,纳入42例符合ASAS标准的中轴型脊柱关节炎患者。
  • 每例患者完成两轮随机双盲交叉比较,比较塞来昔布、美洛昔康和萘普生三种NSAID,每种用药4周。
  • 主要终点为强直性脊柱炎疾病活动度评分(ASDAS)的变化,采用贝叶斯分析基于个体反应评估每种NSAID的平均治疗效果。
  • 试验注册号:ClinicalTrials.gov NCT04115098。

主要发现

  • 30例患者完成试验系列。
  • 三种NSAID在所有个体中总体均使ASDAS下降(获益后验概率>0.99,对应ASDAS下降>0)。
  • 没有单一NSAID在所有患者中显示优越性。
  • 患者偏好各异,贝叶斯分析可识别个体化的NSAID治疗反应。
  • 每例患者的偏好NSAID较最无效NSAID的ASDAS降幅更大(0.88 vs 0.12,获益后验概率>0.99),潜在临床重要改善(获益后验概率[0.6]=0.96)。

临床怎么用

  • 作者认为单病例试验联合贝叶斯分析可优化中轴型脊柱关节炎的NSAID治疗,并可能比常规诊疗更高效地实现系统性个体化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease predominantly affecting the spine and sacroiliac joints. NSAIDs are first-line therapy, but individual responses vary widely. We evaluated the efficacy and patient preference of three NSAIDs (celecoxib, meloxicam and naproxen) through Bayesian N-of-1 clinical trials to optimize axSpA management. METHODS: We conducted N-of-1 trials with 42 patients meeting ASAS criteria for axSpA. Each patient was asked to complete two cycles of randomized double-blind crossover comparisons of the three NSAIDs, each for 4 weeks. The primary end point was the change in the Ankylosing Spondylitis Disease Activity Score (ASDAS). Bayesian analysis assessed the average treatment effect of each NSAID based on individual patient responses. RESULTS: Thirty patients completed the trial series. All three NSAIDs resulted in reductions in ASDAS overall across all individuals (posterior probability of benefit [PPB] >0.99 of >0 reduction). No single NSAID demonstrated superiority across all patients. Patient preferences varied, with individualized responses to NSAID therapy identified through Bayesian analysis. The preferred NSAID for each patient showed a larger reduction in ASDAS compared with the least effective NSAID (0.88 vs 0.12, PPB >0.99), with potential clinically important improvement (PPB [0.6] = 0.96). CONCLUSIONS: Applying N-of-1 trials and Bayesian analysis effectively optimized NSAID therapy for axSpA in terms of efficacy and accounting for side effect profile. This approach raises the possibility of more efficient systemic individualization than usual care. TRIAL REGISTRATION: ClinicalTrials.gov NCT04115098.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hwang MC, Kim S, Assassi S, et al. Individualizing NSAID therapy in axial spondyloarthritis: N-of-1 trials with Bayesian analysis. Rheumatology (Oxford). 2025. PMID: 40676732. doi:10.1093/rheumatology/keaf393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。